2024-10-05 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a leading biotechnology company that develops and commercializes life-saving medicines for serious diseases.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** REGN (97.92%) has significantly underperformed VOO (131.45%) over the historical period.
* **Relative Underperformance:** REGN is currently lagging behind VOO by -33.53%, indicating a 40.8% underperformance relative to its historical range.

**2. Recent Price Action:**

* **Closing Price:** $1040.27
* **5-Day Moving Average:** $1048.18
* **20-Day Moving Average:** $1107.59
* **60-Day Moving Average:** $1117.49

The stock is trading below its 5, 20, and 60-day moving averages, suggesting a downward trend.

**3. Technical Indicators:**

* **RSI (23.63):** The RSI indicates the stock is oversold, suggesting potential for a rebound.
* **PPO (-0.9):**  The PPO signals a negative momentum, confirming the downward trend.
* **Delta_Previous_Relative_Divergence (-26.13):** This indicator shows a recent decline in the stock's relative strength, pointing towards continued downward pressure.
* **Expected Return (0.0%):** The estimated 5-year expected return is currently 0%, suggesting a potential for stagnation compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55B |
| 2024-05-02 | 6.7 | $3.15B |
| 2023-11-02 | 9.48 | $3.36B |
| 2023-08-03 | 9.05 | $3.16B |
| 2024-08-01 | 9.05 | $3.16B |

The most recent earnings report (2024-08-01) shows strong EPS and revenue growth. However, the company's forward guidance needs to be considered for a comprehensive evaluation.

**5. News and Recent Issues:**

* Recent market outlook for REGN is mixed, with some analysts expressing optimism regarding the potential of their pipeline, while others remain cautious due to competitive pressures and challenges in the pharmaceutical industry.
* REGN has been facing challenges in its core Eylea franchise due to the emergence of biosimilars. 
*  The company is focusing on its pipeline, especially for the treatment of inflammatory diseases and oncology.

**6. Overall Analysis:**

REGN is currently facing challenges with its key product Eylea and the overall pharmaceutical landscape. While recent earnings have been positive, the stock is trading below its moving averages, suggesting a downward trend. The RSI indicates oversold conditions, which may suggest potential for a rebound. However, the negative PPO and Delta_Previous_Relative_Divergence indicate that the downward momentum is likely to continue in the near term. The expected return of 0% underscores the potential for stagnation compared to the broader market.

**7. Recommendations:**

* **Short-term:** The current market sentiment suggests that REGN is likely to continue its downward trend. 
* **Long-term:** The company has a promising pipeline and a strong track record of developing innovative medicines, which could drive growth in the long term. 

**Note:** This analysis is based on publicly available data and should not be considered as investment advice. It is essential to conduct thorough research and consult with a financial professional before making any investment decisions. 
